Minute Insight: Abbott’s Aveir VR To Take On Medtronic’s Micra In US Leadless Pacemaker Market
The US FDA approved Aveir VR to treat significant bradycardia on 4 April. It is the world’s only leadless pacemaker with Abbott’s proprietary mapping capability that helps physicians correctly position the device inside the right ventricle.
You may also be interested in...
The FDA approved Abbott’s Aveir DR dual-chamber leadless pacemaker system, which will complement Abbott’s Aveir VR technology and help Abbott compete directly with Medtronic in the growing leadless cardiac rhythm management device market.
About a month after it approved Abbott’s Aveir VR leadless pacemaker, the FDA approved two new models of Medtronic’s Micra leadless pacemaker.
Exec Chat: Abbott Bets On Modular And Leadless Devices To Be The Future Of Cardiac Rhythm Management
Medtech Insight interviewed Leonard Ganz, a veteran cardiac electrophysiologist who recently joined Abbott’s cardiac rhythm management business as its divisional vice president of medical affairs and chief medical officer.